서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 47 of 47

Issue DateTitle / Author(s) / CitationFileAltmetrics
2002-05
Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: A case-control study
DOI
2003-01
Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer
DOI
2004-11
Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma
DOI
2005-01
Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
DOI
2005-04
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
DOI
2005-10
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer
DOI
2005-12
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
DOI
2006-04
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
DOI
2006-09
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells
2007-06
Artificial nutrition and hydration in terminal cancer patients: the real and the ideal
DOI
2007-09
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer
view file
2007-11
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
view fileDOI
2008-05
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
view fileDOI
2008-06
Gemcitabine and Vinorelbine Combination Chemotherapy in Anthracycline- and Taxane-pretreated Advanced Breast Cancer
2008-09
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer
DOI
2008-10
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
view fileDOI
2008-12
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
DOI
2009-07
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy
DOI
2009-09
Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement
DOI
2009-10
Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
view fileDOI
2010-10
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
view fileDOI
2011-03
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
view fileDOI
2011-09
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
DOI
2011-09
VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib
DOI
2011-10
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
DOI
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-08
ABCB1, FCGR2A, and FCGR3A Polymorphisms in Patients with HER2-Positive Metastatic Breast Cancer Who Were Treated with First-Line Taxane plus Trastuzumab Chemotherapy
DOI
2012-09
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
DOI
2012-11
The Lack of CD34 Expression in Gastrointestinal Stromal Tumors is Related to Cystic Degeneration Following Imatinib Use
DOI
2012-12
Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data
view fileDOI
2013-04
Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy
DOI
2013-04
Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer
DOI
2013-07
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
DOI
2013-10
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
DOI
2013-11
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy
DOI
2014-02
A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer A Prospective, Multicenter Trial of the Korean Cancer Study Group
DOI
2014-07
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
DOI
2014-09
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer
DOI
2015-01
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
DOI
2015-06
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DOI
2016-01
Phase I study of CKD-516, a novel vascular disrupting agent, in patients with advanced solid tumors
DOI
2017-07
Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
DOI
2017-07
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
DOI
2018-03
A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2021-05
A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors
DOI
2021-10
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
DOI
1